UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported) January ~~September 20~~7, ~~2007~~ 2009

NEW YORK HEALTH CARE, INC. ~~(Exact Name of Registrant as Specified in Its Charter)~~

New York	1-12451	11-2636089
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
1850 McDonald Avenue, Brooklyn, New York		11223
(Address of Principal Executive Offices)		(Zip Code)
(212) 679-7778
(Registrant's Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since Last Report)

(Exact Name of Registrant as Specified in Its Charter)

New York	1-12451	11-2636089
(State or Other Jurisdiction	(Commission	(IRS Employer
of Incorporation	File Number)	Identification No.)


1850 McDonald Avenue, Brooklyn, New York	11223


(Address of Principal Executive Offices)	(Zip Code)

(212) 679-7778

(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

INFORMATION TO BE INCLUDED IN THE REPORT

~~Item 1.01 Entry into~~Section a8 ~~Material~~- ~~Definitive Agreement.~~Other Events

~~On September~~Item ~~20, 2007, New York Health Care, Inc~~8.01 ~~(the “Company”) entered~~Other into a Loan and Security Agreement with CIT Healthcare LLC, as lender (“Lender”). The term of the Loan and Security Agreement is three years. The Loan and Security Agreement provides for a revolving line of credit facility under which the Company may borrow, repay and re-borrow an amount not exceeding the lesser of $5,000,000 or the borrowing base, which is an amount that may not exceed 85.00% of the estimated net value of the Company’s Eligible Accounts, as defined in the agreement.Events

~~Interest~~New York Health Care, Inc. (the “Company”) has filed a Form 15 today with the Securities and Exchange Commission (“SEC”) to voluntarily deregister its common stock. The Company is ~~payable~~eligible onto ~~the~~deregister ~~outstanding~~because it has fewer than 300 ~~principal~~holders ~~balance~~of record of ~~the~~its ~~credit~~common ~~facility~~stock. atIn anfiling ~~annual~~the ~~rate~~Form ~~equal~~15, tothe ~~30-day~~Company's ~~LIBOR plus~~obligations ~~three~~to file certain reports and ~~one~~forms with the SEC, including Forms 10-~~half~~K, ~~percent~~10-Q ~~(3.50%)~~and 8-K, ~~adjusted~~are ~~monthly~~immediately insuspended. ~~accordance~~The ~~with~~Company ~~changes~~expects inthat ~~30-day~~deregistration ~~LIBOR~~of its common stock will become effective within 90 days.

The Company’s ~~obligations~~is toderegistering ~~Lender~~because it ~~under~~believes that the ~~Loan~~incremental ~~and~~cost ~~Security~~of ~~Agreement~~compliance ~~are~~with ~~secured~~the bySarbanes-Oxley aAct ~~first priority lien~~of ~~on all~~2002 ofand ~~the~~other ~~Company’s~~public ~~accounts~~company ~~receivable,~~reporting ~~general~~requirements ~~intangibles,~~does ~~instruments~~not ~~and~~provide a ~~documents,~~discernable ~~and~~benefit to the ~~proceeds~~Company ~~thereof.~~and ~~However,~~is nonot ~~collateral~~in ~~will~~the ~~consist~~best interests of ~~any assets~~ orits ~~property~~shareholders. ofFactors influencing the Company’'s ~~wholly-owned~~decision ~~subsidiary,~~include ~~The~~the ~~Bio Balance Corp. (“BioBalance”).~~ following:

~~Beginning with~~– The ~~the~~high ~~quarter~~accounting, ~~ended~~legal and administrative ~~September~~costs ~~30,~~of ~~2007,~~preparing ~~the~~and filing ~~Company~~periodic isreports ~~subject~~and toother ~~meeting~~filings ~~periodic~~with ~~financial covenants~~the ~~contained~~SEC in ~~the~~comparison ~~Loan~~to ~~and~~the ~~Security~~size of ~~Agreement~~the Company.

– The ~~Company~~ isneed ~~prohibited~~for ~~from~~senior ~~making~~management ~~dividends, distributions and other withdrawals during the term~~ of the ~~credit facility. However, the~~ Company ~~is permitted~~ to ~~make~~devote ~~loans,~~more ~~advances~~time ~~or contributions~~ to its subsidiary, BioBalance provided that certain liquidity requirements are met. The Company is further restricted from mergers and acquisitions, as well as asset sales or dispositions outside the ~~ordinary course of~~ business, ~~provided that such sale restrictions are not applicable to the sale~~ of the ~~stock or assets of BioBalance~~Company.

~~Item~~– The ~~8.01 Other~~need to maintain the confidentiality of sensitive business information that ~~Events~~would otherwise require SEC disclosure.

– The ~~Bio~~ ~~Balance~~already ~~Corp.~~limited -trading ~~Irritable~~in ~~Bowel~~the ~~Syndrome~~Company's ~~Study~~common stock..

~~BioBalance recently~~– The ~~completed~~fact anthat ~~international,~~current ~~multi-center,~~trading ~~randomized,~~prices ~~double-blind,~~of ~~placebo-controlled,~~the ~~clinical~~common ~~trial~~stock inmake ~~129~~it ~~patients~~unlikely ~~with~~that ~~irritable~~the ~~bowel~~Company could effectively use its common stock to ~~syndrome~~compensate employees, raise capital or make acquisitions.

~~Patients received~~As ~~either~~a 20result mL of ~~ProBactrix~~deregistering (awith ~~probiotic~~the SEC, ~~medical~~the ~~food~~Company's ~~beverage containing~~common 3stock xwill ~~107~~cease ~~colony~~to ~~forming~~be ~~units/mL~~eligible ofto Etrade on the Over-the-Counter Bulletin Board. ~~coli~~The ~~strain~~Company's securities will continue to be ~~M17)~~traded orover athe ~~taste~~counter ~~and~~on ~~appearance~~the ~~matched~~Pink ~~placebo~~Sheets, ~~orally~~but ~~twice~~the Company can make no assurance that any broker will continue to make a ~~day~~market ~~for~~in 12the Company's common ~~weeks~~stock.

ProBactrix-treated patients had significant improvements in stool consistency (p < 0.0001), pain and discomfort (p < 0.007), bloating (p < 0.008), and stool frequency (p < 0.008) at 12 weeks when compared to baseline, which are meaningful quality of life measurements. However, owing to an unusually high placebo response rate (53.1%), there was no statistical difference in the primary endpoint (relief of abdominal pain and discomfort) when ProBactrix- and placebo-treated patients were compared.

ProBactrix was well tolerated. There were more placebo-treated patients who experienced at least one adverse event and who experienced at least one adverse event related to study product (46 and 15, respectively) than did ProBactrix-treated patients (39 and 10, respectively). This study demonstrated the safety of ProBactrix when given for long periods of time and is consistent with other studies that BioBalance has conducted to assess product safety.

Despite the unexpected high placebo response rate and its negative impact on the study’s primary endpoint, BioBalance remains encouraged by the strong improvements in stool consistency, pain and discomfort, bloating, and stool frequency compared to baseline. BioBalance is investigating the use of higher concentrations of the probiotic and plans to review the data derived from the irritable bowel syndrome study as a knowledge base for new studies in order to target indications which the company believes on-going research supports.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits. The following documents are filed as exhibits to this report:

10.1 Loan and Security Agreement, dated September 20, 2007, between New York Health Care, Inc. and CIT Healthcare LLC

10.2 Revolving Credit Note, dated September 20, 2007, delivered by New York Health Care, Inc. to CIT Healthcare LLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, ~~the~~ Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto ~~duly~~ duly authorized.

	NEW YORK HEALTH CARE, INC.
	(Registrant)
Date: September 24, 2007	By:	/s/ Murry Englard
Date: January 7, 2009	By:	/s/ Murry Englard
		Murry Englard
		Murry Englard, Chief Executive Officer
		Title: Chief Executive Officer

EXHIBIT INDEX

Exhibit No.		Description
10.1		Loan and Security Agreement, dated September 20, 2007, between New York Health Care, Inc. and CIT Healthcare LLC
10.2		Revolving Credit Note, dated September 20, 2007, delivered by New York Health Care, Inc. to CIT Healthcare LLC

Filing Compare · NEW YORK HEALTH CARE INC